Zard of switching/discontinuation was considerably larger for adalimumab-treated individuals and
Zard of switching/discontinuation was considerably larger for adalimumab-treated sufferers and certolizumab-treated sufferers. The relative trends across the comparator (nontocilizumab) biologics were commonly comparable for each and every with the two…